Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

Table 5 Base case cost-effectiveness results for 100,000 women over a lifetime time horizon with 100% coverage

Outcome	HPV-16/18 AS04-adjuvanted vaccine plus screening (A)	HPV-6/11/16/18 vaccine plus screening (B)	Difference in outcomes (A – B)
Undiscounted
CIN1 cases	8 217	9 020	−803
CIN2/3 cases	1 294	1 945	−651
Genital warts cases	9 688	2 755	6 933
Cervical cancer cases	113	161	−48
Cervical cancer deaths	38	54	−16
Life Years	7 163 635	7 163 268	367
Quality adjusted life years (QALY)	7 163 094	7 162 817	276
Lifetime cost of strategy	$127 212 309	$129 344 736	-$2 132 427
Incremental cost per QALY gained			A Dominates B
Discounted outcomes
Life Years	2 982 064	2 981 994	70
QALY	2 981 855	2 981 854	1
Lifetime cost of strategy	$75 010 163	$75 693 270	-$683 107
Incremental cost per QALY gained			A Dominates B

ISSN: 1471-2458